[go: up one dir, main page]

DE60005806D1 - Zusammensetzung auf basis gegensätzlich geladener polypeptide - Google Patents

Zusammensetzung auf basis gegensätzlich geladener polypeptide

Info

Publication number
DE60005806D1
DE60005806D1 DE60005806T DE60005806T DE60005806D1 DE 60005806 D1 DE60005806 D1 DE 60005806D1 DE 60005806 T DE60005806 T DE 60005806T DE 60005806 T DE60005806 T DE 60005806T DE 60005806 D1 DE60005806 D1 DE 60005806D1
Authority
DE
Germany
Prior art keywords
composition based
oppositely charged
charged polypeptides
polypeptides
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60005806T
Other languages
English (en)
Other versions
DE60005806T2 (de
Inventor
James Q Oeswein
John R Smikahl
X Wang
A Yeung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DE60005806D1 publication Critical patent/DE60005806D1/de
Publication of DE60005806T2 publication Critical patent/DE60005806T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/808—Optical sensing apparatus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Detergent Compositions (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Hydrogenated Pyridines (AREA)
DE60005806T 1999-04-08 2000-03-30 Zusammensetzung auf basis gegensätzlich geladener polypeptide Expired - Lifetime DE60005806T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12839299P 1999-04-08 1999-04-08
US128392P 1999-04-08
PCT/US2000/008682 WO2000061177A1 (en) 1999-04-08 2000-03-30 Composition based on oppositely-charged polypeptides

Publications (2)

Publication Number Publication Date
DE60005806D1 true DE60005806D1 (de) 2003-11-13
DE60005806T2 DE60005806T2 (de) 2004-08-05

Family

ID=22435148

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60005806T Expired - Lifetime DE60005806T2 (de) 1999-04-08 2000-03-30 Zusammensetzung auf basis gegensätzlich geladener polypeptide

Country Status (13)

Country Link
US (2) US6559122B1 (de)
EP (1) EP1165119B1 (de)
JP (2) JP4360758B2 (de)
AT (1) ATE251466T1 (de)
AU (1) AU763039B2 (de)
CA (1) CA2369451C (de)
DE (1) DE60005806T2 (de)
DK (1) DK1165119T3 (de)
ES (1) ES2208305T3 (de)
HK (1) HK1039065B (de)
IL (1) IL145597A0 (de)
PT (1) PT1165119E (de)
WO (1) WO2000061177A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
WO2000061177A1 (en) * 1999-04-08 2000-10-19 Genentech, Inc. Composition based on oppositely-charged polypeptides
DE60120372T2 (de) * 2000-03-24 2007-07-05 Genentech Inc., San Francisco Verwendung von insulin zur behandlung von knorpelkrankheiten
PT1946776T (pt) * 2002-02-27 2017-03-17 Immunex Corp Composição de tnfr-fc estabilizada compreendendo arginina
EP1523326A4 (de) * 2002-05-06 2009-09-09 Univ Jefferson Insulin-assoziierte peptide zur besserung der gehirnwirkung
US7655618B2 (en) * 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
CA2509755A1 (en) * 2002-12-27 2004-07-22 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
BRPI0416042A (pt) * 2003-11-13 2007-01-02 Alza Corp composição e aparelho para suprimento transdérmico
EP1733037B1 (de) * 2004-03-11 2014-11-05 Genentech, Inc. Verfahren zur herstellung von polypeptiden
KR101725225B1 (ko) 2004-04-23 2017-04-12 사이덱스 파마슈티칼스, 인크. 술포알킬 에테르 시클로덱스트린 함유 ｄｐｉ 제형
EP1674113A1 (de) 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Konjugate von insulinähnlichem Wachstumfaktor-1 und Poly(Ethylenglykol)
ES2776657T3 (es) 2005-06-14 2020-07-31 Amgen Inc Formulaciones de proteínas autotamponantes
KR101105871B1 (ko) * 2005-09-27 2012-01-16 주식회사 엘지생명과학 인 난포자극호르몬의 안정한 용액 제형
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
MX2009001691A (es) * 2006-08-31 2009-02-25 Hoffmann La Roche Metodo para produccion del factor de crecimiento i tipo insulina.
CL2007002502A1 (es) 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
KR20100119899A (ko) * 2008-04-03 2010-11-11 에프. 호프만-라 로슈 아게 폴리에틸렌글리콜화된 인슐린 유사 성장 인자 분석법
US20110152188A1 (en) * 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
US20110207764A1 (en) * 2010-02-23 2011-08-25 Valery Alakhov Cyclopolysaccharide compositions
US8383663B2 (en) 2010-07-19 2013-02-26 Supratek Pharma Inc. Bendamustine anionic-catioinic cyclopolysaccharide compositions
CN105188759A (zh) * 2013-03-14 2015-12-23 阿勒根公司 持续释放递送的组合物以及在制造过程中稳定蛋白质的方法
CA3040899A1 (en) 2016-10-21 2018-04-26 Amgen Inc. Pharmaceutical formulations and methods of making the same

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207842A (en) 1983-04-25 1988-02-12 Chiron Corp Production of human insulin-like growth factor (igf) using cdna
IL71991A (en) 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
DE3326473A1 (de) 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt Pharmazeutisches mittel zur behandlung des diabetes mellitus
EP0235205B1 (de) 1985-08-22 1992-10-28 Gropep Pty. Ltd. Peptidanalogedes insulinähnlichen wachstumsfaktors-1 bei säugetieren
SE8505922D0 (sv) 1985-12-13 1985-12-13 Kabigen Ab Construction of an igg binding protein to facilitate downstream processing using protein engineering
CA1314507C (en) 1987-04-23 1993-03-16 Edith Yee-Tak Wong Secretion of insulin-like growth factor-i in e. coli
US4876242A (en) 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
KR930008447B1 (ko) 1987-10-23 1993-09-04 쉐링 코포레이션 단백질 정제방법
ATE116335T1 (de) 1987-12-24 1995-01-15 Gropep Pty Ltd Peptid-analoge vom insulinähnlichen wachstums- faktor 1 (igf-1) oder faktor 2 (igf-2).
US5470828A (en) 1987-12-24 1995-11-28 Gropep Pty. Ltd. Peptide analogs of insulin-like growth factor II
US4988675A (en) 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
US5091173A (en) 1989-06-29 1992-02-25 The University Of Dundee Hair growth composition
GB8920381D0 (en) 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes
JPH0818999B2 (ja) 1990-01-05 1996-02-28 藤沢薬品工業株式会社 インシュリン様成長因子ｉの乾燥製剤
US5681814A (en) 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
US5374620A (en) 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
US5126324A (en) 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
AU671964B2 (en) 1991-12-05 1996-09-19 Alfatec-Pharma Gmbh Peroral administration form for peptidic medicaments, in particular insulin
US5614219A (en) 1991-12-05 1997-03-25 Alfatec-Pharma Gmbh Oral administration form for peptide pharmaceutical substances, in particular insulin
SE9201573D0 (sv) 1992-05-19 1992-05-19 Kabi Pharmacia Ab Use of igf-1
SE9300105D0 (sv) 1993-01-15 1993-01-15 Kabi Pharmacia Ab Stable protein solution
CA2132871A1 (en) 1993-01-25 1994-08-04 Alan C. Moses Method for modifying, diagnosing, and screening for igf-i sensitive cell barrier properties
SE9402119D0 (sv) 1994-06-16 1994-06-16 Pharmacia Ab Solution
SE9402331D0 (sv) 1994-07-01 1994-07-01 Pharmacia Ab New use
SE9402370D0 (sv) 1994-07-04 1994-07-04 Pharmacia Ab Use of IGF-I
US5788959A (en) 1995-04-24 1998-08-04 University Of Maryland, Baltimore County Drug delivery device and method for employing the same
DK0986404T3 (da) 1996-07-10 2002-05-13 West Pharm Serv Drug Res Ltd Genterapi-indgivelsessystem målrettet til endotel
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
ZA984697B (en) 1997-06-13 1999-12-01 Lilly Co Eli Stable insulin formulations.
WO1999024063A1 (en) 1997-11-07 1999-05-20 Chiron Corporation Compositions providing for increased igf-i solubility
WO2000061177A1 (en) * 1999-04-08 2000-10-19 Genentech, Inc. Composition based on oppositely-charged polypeptides

Also Published As

Publication number Publication date
EP1165119B1 (de) 2003-10-08
PT1165119E (pt) 2004-02-27
AU763039B2 (en) 2003-07-10
WO2000061177A1 (en) 2000-10-19
HK1039065A1 (en) 2002-04-12
AU4061300A (en) 2000-11-14
ES2208305T3 (es) 2004-06-16
US7186686B2 (en) 2007-03-06
CA2369451A1 (en) 2000-10-19
DE60005806T2 (de) 2004-08-05
JP4360758B2 (ja) 2009-11-11
DK1165119T3 (da) 2003-12-15
CA2369451C (en) 2009-09-22
US6559122B1 (en) 2003-05-06
JP2009029803A (ja) 2009-02-12
HK1039065B (en) 2004-04-16
ATE251466T1 (de) 2003-10-15
US20030195142A1 (en) 2003-10-16
JP2002541212A (ja) 2002-12-03
EP1165119A1 (de) 2002-01-02
WO2000061177A9 (en) 2002-04-18
IL145597A0 (en) 2002-06-30

Similar Documents

Publication Publication Date Title
DE60005806D1 (de) Zusammensetzung auf basis gegensätzlich geladener polypeptide
ATE196296T1 (de) Dolastatin analog
ATE380822T1 (de) Funf-helix protein
BR0114994A (pt) Composição de vacina
CO5540371A2 (es) Administracion pulmonar de insulina quimicamente modificada
NO933028D0 (no) Peg-interferonkonjugater
TR199701544T1 (xx) Yeni dolastatin t�revleri,bunlar�n haz�rlanmas� ve kullan�lmas�.
BR0305074A (pt) Composições cosméticas com alta afinidade
UY24572A1 (es) Conjugados peg - interferon alfa
PT689459E (pt) Novo agente para o controlo da actividade celular
BR0215266A (pt) Preparação liofilizada compreendendo anticorpos contra o receptor de egf
DE69417252D1 (de) Verbesserte immunogene zusammensetzung gegen mensliches gastrin 17
DE69126568D1 (de) Neues physiologisch aktives Schweinepeptid (CNP-53)
BR0011040A (pt) Revestimento de pó de mate
IL187595A0 (en) Antitumor antibodies, proteins, and uses thereof
AU2001248822A1 (en) Gd3-mimetic peptides
DK0921793T3 (da) Faste, ikke-henflydende formuleringer af natriumvalproat
GB9914045D0 (en) Novel compounds
NZ232564A (en) Pseudomonas exotoxin a, pe40 domain derivatives conjugated to a protein targeting domain
AU5347898A (en) Method of coupling polysaccharides to proteins
DE69737476D1 (de) Neuer galaninrezeptor
MX9800967A (es) Compuestos quimicos.
ES1054933Y (es) Colector de orina perfeccionado de uso femenino.
AU2001237784A1 (en) Method for fixing that part of a flashing, made of lead-replacement material, that is fitted in a joint between two structural components, and clamping body to be used for this
IT1262906B (it) Proteine funzionalizzate e loro uso per la preparazione di traccianti coniugati

Legal Events

Date Code Title Description
8364 No opposition during term of opposition